Indication:
Drug Name- Xtandi
Active Ingredient - Enzaludamide
To treat men with late stage metastatic castration resistent prostrate cancer
that has spread or recurred even with medical or surgical therapy to
minimize testosterone
Indication-
To treat men with late stage metastatic castration resistent prostrate cancer
that has spread or recurred even with medical or surgical therapy to
minimize testosterone
Approved by FDA on 31-8--2012 (Ref- FDA Approved List- 2012)
LIST OF APPROVED DRUG FROM 01-01-2015 To 31-12-2015
ISSUED BY NEW DRUG DIVISION - DRUG CONTROLLER GENERAL- INDIA
Sr.No Name of Drug Indication Date of Issue
17. Enzalutamide 40mg soft Capsule 18-12-2015
For the treatment of adults with metastatic
castration resistent prostrate cancer whose
disease has progressed on or after
Doxetaxel therap
Approved by DCG INDIA (Ref- DCGI approved List- 01-01-2015 To 31-12-3015)
Dosages/ Overdosage Etc:
Indication-
To treat men with late stage metastatic castration resistent prostrate cancer
that has spread or recurred even with medical or surgical therapy to
minimize testosterone
Manufacturer Details